Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.09)
# 540
Out of 5,105 analysts
233
Total ratings
54.61%
Success rate
11.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $12.88 | -6.83% | 3 | Dec 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $167.50 | +22.39% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $8.46 | +124.59% | 5 | Nov 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $178 → $173 | $152.80 | +13.22% | 31 | Nov 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $113.56 | +13.60% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $50.49 | +52.51% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $40.94 | +92.97% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $75.64 | -6.13% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $11.92 | +134.90% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $11.63 | +80.57% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $3.60 | -44.44% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $7.45 | +74.50% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $10.55 | +923.70% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $36.23 | +51.81% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $27.15 | -11.60% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $91.85 | -7.46% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $26.51 | +1.85% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $63.35 | +5.76% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.45 | +314.20% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.71 | +133.92% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $2.32 | +72.41% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.08 | +130.26% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.23 | +18.20% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.85 | -22.08% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $2.14 | +554.21% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.60 | +525.00% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $40.88 | -46.18% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $11.53 | +1,187.94% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.93 | +6,317.80% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.39 | +36.67% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $11.31 | +5,631.98% | 6 | May 8, 2020 |
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $12.88
Upside: -6.83%
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $167.50
Upside: +22.39%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $8.46
Upside: +124.59%
Neurocrine Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $178 → $173
Current: $152.80
Upside: +13.22%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $113.56
Upside: +13.60%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $50.49
Upside: +52.51%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $40.94
Upside: +92.97%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $75.64
Upside: -6.13%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $11.92
Upside: +134.90%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $11.63
Upside: +80.57%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $3.60
Upside: -44.44%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.45
Upside: +74.50%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $10.55
Upside: +923.70%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $36.23
Upside: +51.81%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $27.15
Upside: -11.60%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $91.85
Upside: -7.46%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $26.51
Upside: +1.85%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $63.35
Upside: +5.76%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.45
Upside: +314.20%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.71
Upside: +133.92%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.32
Upside: +72.41%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.08
Upside: +130.26%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.23
Upside: +18.20%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.85
Upside: -22.08%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $2.14
Upside: +554.21%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.60
Upside: +525.00%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $40.88
Upside: -46.18%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $11.53
Upside: +1,187.94%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.93
Upside: +6,317.80%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.39
Upside: +36.67%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $11.31
Upside: +5,631.98%